Research & Development

01 Apr 2020
- Drug Discovery
- Research & Development
VBI Vaccines collaborates with the National Research Council of Canada to develop pan-coronavirus vaccine candidate

By PBR Staff Writer

VBI Vaccines, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with the National Research Council of Canada (NRC), Canada’s largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).
01 Apr 2020
Drug Discovery
Research & Development
Eli Lilly, Sitryx sign potential $880m deal to develop immunometabolic medicines

By PBR Staff Writer

Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines.
31 Mar 2020
Drug Discovery
Research & Development
Aptorum to investigate use of repurposed drug candidates for coronavirus

By PBR Staff Writer

Aptorum Group has joined forces with Covar Pharmaceuticals for studying the use of three repurposed drug candidates for the treatment of novel coronavirus (COVID-19).
30 Mar 2020
Drug Discovery
Research & Development
Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease

By PBR Staff Writer

Sanofi’s vaccines global business unit Sanofi Pasteur has collaborated with Translate Bio for the development of a novel messenger RNA (mRNA) vaccine for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
27 Mar 2020
Drug Discovery
Research & Development
Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease

By PBR Staff Writer

Novartis and a consortium of life sciences companies have collaborated with Bill & Melinda Gates Foundation (BMGF) to advance the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
26 Mar 2020
Drug Discovery
Research & Development
ClinOne’s remote clinical trial patient management technology allows pharmaceutical companies to continue clinical research efforts amidst Covid-19 pandemic in accordance with FDA guidelines

By PBR Staff Writer

The Covid-19 pandemic has shined a bright light on the need to manage patients remotely wherever possible.
26 Mar 2020
Drug Discovery
Research & Development
Xencor, Vir Biotechnology collaborate on Xtend XmAb antibody technology for COVID-19

By PBR Staff Writer

Xencor and Vir Biotechnology have entered into a technology licence agreement for the use of Xtend XmAb Fc technology in investigational antibodies for the treatment of COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
23 Mar 2020
Drug Discovery
Research & Development
Design Therapeutics launches with $45m to develop a new class of disease-modifying therapies for serious degenerative disorders

By PBR Staff Writer

Design Therapeutics announced today that it is launching to create and develop a new class of therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions.
19 Mar 2020
Drug Discovery
Research & Development
Entos to develop Fusogenix DNA vaccine to prevent COVID-19 infections

By PBR Staff Writer

Healthcare biotechnology company Entos Pharmaceuticals has unveiled plans to develop a Fusogenix DNA vaccine for the prevention of COVID-19 infections.
18 Mar 2020
Drug Discovery
Research & Development
RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration

By PBR Staff Writer

RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Malaysia, Cambodia and Myanmar; hereinafter "the Territory").

Drug Discovery

Research & Development

Teva receives FDA approval for Prolia biosimilar

uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Research & Development

VBI Vaccines collaborates with the National Research Council of Canada to develop pan-coronavirus vaccine candidate

Eli Lilly, Sitryx sign potential $880m deal to develop immunometabolic medicines

Aptorum to investigate use of repurposed drug candidates for coronavirus

Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease

Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease

ClinOne’s remote clinical trial patient management technology allows pharmaceutical companies to continue clinical research efforts amidst Covid-19 pandemic in accordance with FDA guidelines

Xencor, Vir Biotechnology collaborate on Xtend XmAb antibody technology for COVID-19

Design Therapeutics launches with $45m to develop a new class of disease-modifying therapies for serious degenerative disorders

Entos to develop Fusogenix DNA vaccine to prevent COVID-19 infections

RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found